16
INSULIN-OLD & NEW BY Dr. GOURI ORAM

Insulin old & new

Embed Size (px)

Citation preview

Page 1: Insulin old & new

INSULIN-OLD & NEW

BY

Dr. GOURI ORAM

Page 2: Insulin old & new

INTRODUCTION

Insulin is a hormone that is important for metabolism and utilization of energy from the ingested nutrients - especially glucose.

Insulin is produced in the islets of Langerhans in the pancreas. The name insulin comes from the Latin ''insula'' for "island" from the cells that produce the hormone in the pancreas.

Insulin's structure varies slightly between species of animal. Both porcine (from pigs) and bovine (from cows) insulin are similar to human insulin but porcine insulin resembles human insulin more closely.

Page 3: Insulin old & new

Dr. Nicolae Paulescu , Romanian scientist invented Insulin in 1916.

On January 11, 1922 Leonard Thomson a 14 year old boy who was dyeing of Diabetes , was given the first experimental dose of insulin and his life saved.

In 1923 , Banting and Macleod were awarded the noble prize for their work on discovering insulin.

Page 4: Insulin old & new

WHAT DOES INSULIN DO ?

It causes the cells in the liver, muscle, and fat tissue to take up glucose from blood and convert it to glycogen that can be stored in the liver and muscles.

Insulin also prevents the utilization of fat as an energy source. In absence of insulin or in conditions where insulin is low glucose is not taken up by body cells, and the body begins to use fat as an energy source.

Insulin also controls other body systems and regulates the amino acid uptake by body cells.

It has several other anabolic effects throughout the body as well.

Page 5: Insulin old & new
Page 6: Insulin old & new

INDICATIONS OF INSULIN THERAPY

At onset : Fasting > 250 mg /dl

Post prandial > 300mg/dl

HbA1c > 9.0%

OHA Failure Fasting >150mg/dl

Random or Post prandial > 200mg/dl

HbA1c >8.5%

Co-morbid conditions Severe systemic infection or sepsis

Acute Myocardial Infarction / Unstable Angina

Diabetic Ketoacidosis/Hyperosmolar state

Diabetic Kidney Disease

Pre - gestational / Gestational Diabetes

Page 7: Insulin old & new

TYPES OF INSULIN

Duration of action ( in hours ) of insulin preparations

Insulin Onset

Peak

Duration

Rapid- acting (insulin analogues: lispro,aspart, glulisine)

<0.5 0.5-2.5 3-4.5

Short –acting soluble(regular)

0.5-1 1-4 4-8

Intermediate – acting( isophane (NPH) , lente)

1-3 3-8 7-14

Long-acting(bovine ultralenti)

2-4 6-12 12-30

Long-acting(insulin analogues:glargine,detemir)

1-2 None 18-24

Page 8: Insulin old & new

INSULIN INJECTIONS AND SITES

Page 9: Insulin old & new

INSULIN DELIVERY DEVICES

Insulin syringes External Insulin Pumps Implantable Insulin Pumps Insulin Pens Insulin Injection Aids Insulin Jet Injectors Insulin Inhalers

Page 10: Insulin old & new
Page 11: Insulin old & new

INSULIN DOSING REGIMENS

Degree of glycaemic control. Severity of underlying insulin deficiency. Patient’s lifestyle. His/Her ability to adjust the insulin dose.

(SMBG)

Page 12: Insulin old & new

TYPE OF INSULIN FOR INSULIN INITIATION

Insulin initiation could be done with premixed insulins which control effectively both fasting and post prandial hyperglycemia.

Premixed formulations are generally available as 30/70, 25/75 or 50,50 combinations of rapid acting and intermediate acting insulins.

The gold standard for insulin regimen is basal bolus therapy combining one or two doses of basal insulins and three doses of rapid acting insulins to cover the post prandial peaks following three major meals.

Page 13: Insulin old & new

Titration Algorithm ( Premixed Insulin)

Pre meal blood glucose Change in Insulin dose(U)

<100mg/dl -2

100-140mg/dl 0

111-140mg/dl +2

141-180mg/dl +4

>180mg/dl +6

Page 14: Insulin old & new

SIDE EFFECTS OF INSULIN THERAPY

Hypoglycaemia (<63mg/dl) Weight gain Peripheral oedema( salt and water retention) Insulin antibodies Local allergy ( rare ) Lipodystrophy at injection sites.

Page 15: Insulin old & new

CONCLUSION

There is evidence demonstrating that fasting plasma glucose(FPG) should be the key focus in initial management of patients with poor glycaemic control,while postprandial glycaemia should be targeted in patients with lower HbA1c.

Controlling glycaemia is an important part of this integrated multifactorial approach and maintaining glycaemic levels as close to the non-diabetic range as possible and is essential in preventing microvascular as well as macrovascular complications.

The gold standard for insulin regimen is basal bolus therapy combining one or two doses of insulins and three doses of rapid acting insulins to cover the postprandial peaks following three rapid meals.

Page 16: Insulin old & new

THANK YOU